Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 7/2019

01-07-2019 | Vaccination | Original Article

Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma

Authors: Sonja Ludwig, Chang-Sook Hong, Beatrice M. Razzo, Kellsye P. L. Fabian, Manoj Chelvanambi, Stephan Lang, Walter J. Storkus, Theresa L. Whiteside

Published in: Cancer Immunology, Immunotherapy | Issue 7/2019

Login to get access

Abstract

Advanced oral squamous cell carcinomas (OSCC) have limited therapeutic options. Although immune therapies are emerging as a potentially effective alternative or adjunct to chemotherapies, the therapeutic efficacy of combination immune chemotherapies has yet to be determined. Using a 4-nitroquinolone-N-oxide (4NQO) orthotopic model of OSCC in immunocompetent mice, we evaluated the therapeutic efficacy of single- and combined-agent treatment with a poly-epitope tumor peptide vaccine, cisplatin and/or an A2AR inhibitor, ZM241385. The monotherapies or their combinations resulted in a partial inhibition of tumor growth and, in some cases, a significant but transient upregulation of systemic anti-tumor CD8+ T cell responses. These responses eroded in the face of expanding immunoregulatory cell populations at later stages of tumor progression. Our findings support the need for the further development of combinatorial therapeutic approaches that could more effectively silence dominant immune inhibitory pathways operating in OSCC and provide novel, more beneficial treatment options for this tumor.
Appendix
Available only for authorised users
Literature
1.
2.
Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11(1):9–22CrossRefPubMed
3.
Ferlay J et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386CrossRefPubMed
4.
Whiteside TL (2018) Head and neck carcinoma immunotherapy: facts and hopes. Clin Cancer Res 24(1):6–13CrossRefPubMed
5.
Melero I et al (2018) Introducing a new series: immunotherapy facts and hopes. Clin Cancer Res 24(8):1773–1774CrossRefPubMed
6.
Economopoulou P et al (2016) The promise of immunotherapy in head and neck squamous cell carcinoma. Ann Oncol 27(9):1675–1685CrossRefPubMed
7.
Cekic C et al (2014) Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res 74(24):7250–7259CrossRefPubMedPubMedCentral
8.
9.
Mandapathil M et al (2010) Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 285(36):27571–27580CrossRefPubMedPubMedCentral
10.
Di Virgilio F, Adinolfi E (2017) Extracellular purines, purinergic receptors and tumor growth. Oncogene 36(3):293–303CrossRefPubMed
11.
Mediavilla-Varela M et al (2017) A novel antagonist of the immune checkpoint protein adenosine A2a receptor restores tumor-infiltrating lymphocyte activity in the context of the tumor microenvironment. Neoplasia 19(7):530–536CrossRefPubMedPubMedCentral
12.
Goetzl EJ, An S, Zeng L (1995) Specific suppression by prostaglandin E2 of activation-induced apoptosis of human CD4+CD8+ T lymphoblasts. J Immunol 154(3):1041–1047PubMed
13.
14.
15.
Hutchinson L (2015) Immunotherapy: evading immune escape: synergy of COX and immune-checkpoint inhibitors. Nat Rev Clin Oncol 12(11):622PubMed
16.
Beavis PA et al (2015) Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res 3(5):506–517CrossRefPubMed
17.
18.
19.
20.
Liu Z et al (2017) Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4(+) T cells combined with agonist alpha-GITR mAb promotes durable CD8(+) T-cell-dependent antitumor immunity. Oncoimmunology 6(6):e1315487CrossRefPubMedPubMedCentral
21.
Arab S et al (2017) Increased efficacy of a dendritic cell-based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor. Tumour Biol 39(3):1010428317695021CrossRefPubMed
22.
Leone RD, Lo YC, Powell JD (2015) A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J 13:265–272CrossRefPubMedPubMedCentral
23.
Hawkins BL et al (1994) 4NQO carcinogenesis: a mouse model of oral cavity squamous cell carcinoma. Head Neck 16(5):424–432CrossRefPubMed
24.
25.
Yang Z et al (2013) Comparable molecular alterations in 4-nitroquinoline 1-oxide-induced oral and esophageal cancer in mice and in human esophageal cancer, associated with poor prognosis of patients. Vivo 27(4):473–484
26.
Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24(3):148–154CrossRefPubMed
27.
Qu Y et al (2010) Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment. J Immunol 185(5):2895–2902CrossRefPubMed
28.
29.
Son YI et al (2002) A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells. J Immunol Methods 262(1–2):145–157CrossRefPubMed
30.
Zhao X et al (2012) Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol 188(4):1782–1788CrossRefPubMed
31.
Liu Q et al (2018) BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma. Cancer Immunol Immunother 67(2):299–310CrossRefPubMed
32.
Hatano M et al (2004) Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med 2(1):40CrossRefPubMedPubMedCentral
33.
Umano Y et al (2001) Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br J Cancer 84(8):1052–1057CrossRefPubMedPubMedCentral
34.
Lacabanne V et al (1996) A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells. Eur J Immunol 26(11):2635–2639CrossRefPubMed
35.
Hofmann UB et al (2009) Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes. Eur J Immunol 39(5):1419–1424CrossRefPubMed
36.
Dong Y et al (2006) Identification of H-2Db-specific CD8 + T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. J Immunother 29(1):32–40CrossRefPubMed
37.
Waickman AT et al (2012) Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother 61(6):917–926CrossRefPubMed
38.
Fabian KP et al (2017) Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice. Oncoimmunology 6(3):e1290035CrossRefPubMedPubMedCentral
39.
Theodoraki MN et al (2018) Clinical significance of PD-L1(+) exosomes in plasma of head and neck cancer patients. Clin Cancer Res 24(4):896–905CrossRefPubMed
40.
Chen WC et al (2017) Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck. Head Neck 39(2):347–355CrossRefPubMed
41.
Chu M et al (2012) Myeloid-derived suppressor cells contribute to oral cancer progression in 4NQO-treated mice. Oral Dis 18(1):67–73CrossRefPubMed
42.
Fuse H et al (2016) Enhanced expression of PD-L1 in oral squamous cell carcinoma-derived CD11b(+)Gr-1(+) cells and its contribution to immunosuppressive activity. Oral Oncol 59:20–29CrossRefPubMed
43.
Schaefer C et al (2005) Characteristics of CD4 + CD25 + regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 92(5):913–920CrossRefPubMedPubMedCentral
44.
Mandapathil M et al (2009) Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res 15(20):6348–6357CrossRefPubMedPubMedCentral
45.
Jie HB et al (2013) Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 109(10):2629–2635CrossRefPubMedPubMedCentral
46.
Theodoraki MN, Hoffmann TK, Whiteside TL (2018) Separation of plasma-derived exosomes into CD3((+)) and CD3((−)) fractions allows for association of immune cell and tumour cell markers with disease activity in HNSCC patients. Clin Exp Immunol 192(3):271–283CrossRefPubMed
47.
Liu JF et al (2018) Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer. Mol Carcinog 57(3):429–439CrossRefPubMed
48.
49.
Schuler PJ et al (2014) Human CD4 + CD39 + regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73 + exosomes or CD73 + cells. Clin Exp Immunol 177(2):531–543CrossRefPubMedPubMedCentral
Metadata
Title
Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma
Authors
Sonja Ludwig
Chang-Sook Hong
Beatrice M. Razzo
Kellsye P. L. Fabian
Manoj Chelvanambi
Stephan Lang
Walter J. Storkus
Theresa L. Whiteside
Publication date
01-07-2019
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 7/2019
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-019-02348-2

Other articles of this Issue 7/2019

Cancer Immunology, Immunotherapy 7/2019 Go to the issue

Original Article

Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma

Original Article

Cryptotanshinone has curative dual anti-proliferative and immunotherapeutic effects on mouse Lewis lung carcinoma

Review

PLAC1: biology and potential application in cancer immunotherapy

Original Article

Metabolic remodeling contributes towards an immune-suppressive phenotype in glioblastoma

Original Article

Clinicopathological implications of TIM3+ tumor-infiltrating lymphocytes and the miR-455-5p/Galectin-9 axis in skull base chordoma patients

Original Article

Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits